Power Wheelchair Group 2 denied for failing step therapy by UnitedHealthcare?

UnitedHealthcare's Commercial policy states that mobility devices including manual wheelchairs, electric wheelchairs, transfer chairs, scooters/power-operated vehicles (POVs), canes, and walkers are a covered health care service when medically necessary. The policy applies the Medicare DME MAC LCD for Power Mobility Devices (L33789) criteria, which require that the beneficiary has a mobility limitation that significantly impairs his/her ability to participate in one or more mobility-related activities of daily living (MRADLs) such as toileting, feeding, dressing, grooming, and bathing in customary locations in the home, where the mobility limitation prevents the beneficiary from accomplishing an MRADL entirely, places the beneficiary at heightened risk of morbidity or mortality, or prevents completion within a reasonable time frame. The beneficiary's mobility limitation cannot be sufficiently and safely resolved by an appropriately fitted cane or walker, and the beneficiary does not have sufficient upper extremity function to self-propel an optimally-configured manual wheelchair in the home to perform MRADLs during a typical day. For a Group 2 Single Power Option PWC (K0835–K0840), all basic coverage criteria (a)–(e) must be met, plus the beneficiary requires a drive control interface other than a hand or chin-operated standard proportional joystick (e.g., head control, sip and puff, switch control), OR meets coverage criteria for a power tilt or power recline seating system being used on the wheelchair, AND has had a specialty evaluation performed by a licensed/certified medical professional (PT, OT, or practitioner) with specific training and experience in rehabilitation wheelchair evaluations documenting medical necessity. The wheelchair must be provided by a supplier that employs a RESNA-certified Assistive Technology Professional (ATP) who specializes in wheelchairs and has direct, in-person involvement in the wheelchair selection. Section 6407 of the ACA requires a face-to-face encounter, documented by a physician (or NP, PA, or CNS), occurring within the 6 months before the order is written for the DME. Weight-class criteria apply: a Heavy Duty PWC is covered for beneficiaries weighing 285–450 pounds, Very Heavy Duty for 428–600 pounds, and Extra Heavy Duty for 570 pounds or more. Payment is made for only one wheelchair at a time; backup chairs are denied as not reasonable and necessary.

- **Document in-home MRADL impairment in detail** — Provide specific examples of how the member cannot independently/safely complete toileting, feeding, dressing, grooming, or bathing in the home, mapping directly to the LCD MRADL definition: a mobility limitation that prevents accomplishment of an MRADL, places the beneficiary at heightened risk of morbidity/mortality, or prevents completion within a reasonable time frame. - **Demonstrate failure of lesser alternatives** — Include PT/OT trial documentation showing that the beneficiary lacks sufficient upper extremity function to self-propel an optimally-configured manual wheelchair in the home to perform MRADLs during a typical day due to weakness, fatigue, pain, ROM limits, or absent extremities, satisfying LCD basic criterion C. - **Submit a compliant specialty evaluation and ATP attestation** — Provide the LCMP/PT/OT evaluation with the no-financial-relationship attestation per the requirement of a signed and dated attestation by the supplier or LCMP that the LCMP has no financial relationship with the supplier , plus documentation that the wheelchair is provided by a supplier that employs a RESNA-certified Assistive Technology Professional (ATP) who specializes in wheelchairs and has direct, in-person involvement in the wheelchair selection. - **Justify the Group 2 power option upgrade** — For K0835–K0840, document either a non-standard drive control need (head control, sip-and-puff, switch) OR concurrent need for a power tilt/recline system per the LCD requirement that the beneficiary requires a drive control interface other than a hand or chin-operated standard proportional joystick, or meets coverage criteria for a power tilt or power recline seating system being used on the wheelchair. - **Provide a timely 7-element order and face-to-face note** — Submit the in-window F2F note and order; per the LCD policy article, the 7-element order must be received by the supplier within 45 days after completion of the face-to-face examination , and per CMS, the encounter must occur within the 6 months before the order is written. - **Verify accurate weight-class coding** — Confirm the member's weight aligns with the prescribed class boundaries set by the LCD: Heavy Duty 285–450 lb, Very Heavy Duty 428–600 lb, and Extra Heavy Duty 570 lb or more , and amend the HCPCS code if a misclassification triggered the denial. - **Cite clinical/professional standards** — Reference RESNA's position papers on the application of power wheelchairs and seat-elevation/tilt systems, and AOTA/APTA wheelchair assessment guidelines, to support the medical necessity narrative that mirrors LCD L33789 — the framework UnitedHealthcare explicitly adopts via its Mobility Devices policy and the DME MAC LCD for Power Mobility Devices (L33789).

## UnitedHealthcare Medicare Advantage Step-Therapy Denial — Group 2 Power Wheelchair (K0835–K0843)

A UHC Medicare Advantage step-therapy denial on a Group 2 PWC almost never means UHC has invented its own step. It means UHC's DME utilization management team — operating under the Coverage Summary that delegates to DME MAC LCD L33789 — has concluded the face-to-face mobility evaluation failed to walk through the PMD Coverage Algorithm: cane/walker → optimally-configured manual wheelchair → POV/scooter → PWC. If any rung is not affirmatively excluded in the clinician's note, UHC's reviewer (commonly an Optum-affiliated medical director, though DME UM for UHC MA is run inside UHC's own clinical services line, not Optum Rx) issues a step-therapy / "lesser device not ruled out" denial under LCD L33789 criteria (a)–(e).

The procedural posture matters. This is a Medicare Advantage organization determination under 42 CFR §422.566, not an ERISA NQTL parity dispute — so 29 USC §1185d step-therapy override rights do not apply. The appeal track is 42 CFR §422.582 (reconsideration) → IRE review by MAXIMUS Federal Services under 42 CFR §422.592 → ALJ. If the member has lost ambulation and cannot safely toilet/transfer, file an expedited reconsideration under §422.584 — UHC has 72 hours.

The substantive fix is documentation, not rhetoric. The F2F mobility examination must affirmatively state, in the treating practitioner's own words, that (1) the beneficiary's MRADL limitation cannot be resolved by a cane or walker, (2) the beneficiary lacks sufficient upper-extremity function, endurance, or postural stability to self-propel an optimally configured manual wheelchair within a reasonable timeframe in the home, and (3) a POV/scooter is inadequate — typically because the home cannot accommodate the scooter's turning radius or the beneficiary cannot safely transfer to/from a tiller-steered device. For K0835–K0840 (Single Power Option) add the licensed PT/OT specialty evaluation documenting the need for a non-proportional drive control or power tilt/recline. For K0841–K0843 (Multiple Power Option) the note must tie the limitation to a neurological condition, myopathy, or congenital skeletal deformity, or document ventilator dependence. Pair the F2F with the 7-element Standard Written Order dated before delivery per LCD L33789 — a missing or post-dated SWO is the second-most-common UHC denial pillar after the algorithm gap.

Escalation lever: UHC MA plans are bound by the same DME MAC LCD their commercial counterparts cite, but they are not permitted to add coverage criteria beyond what CMS national/local policy allows (42 CFR §422.101(b)(2)). If UHC's denial letter cites a stricter "medical necessity" standard than LCD L33789 itself — for example, requiring a manual wheelchair trial period not in the LCD — that is appealable as an impermissible MA coverage restriction.

Tactical tip: Pull the supplier's CMN/F2F packet and highlight, with a cover letter, the exact paragraph where each PMD-algorithm rung is excluded. Submit the RESNA-certified ATP evaluation as a separate exhibit (not buried in the supplier's order). For expedited cases, fax the appeal directly to the UHC MA Appeals & Grievances unit listed on the denial — do not route through the supplier portal, which adds 5–7 business days.